ACADIA Pharmaceuticals Inc Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin - Corporate Call Transcript
Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals conference call to discuss the ADVANCE study results. My name is Catherine, and I'll be your coordinator for today. (Operator Instructions)
I would now like to turn the presentation over to Mr. Mark Johnson, Vice President of Investor Relations at ACADIA. Please proceed.
Thank you, Catherine. Good afternoon, and thank you for joining us on today's call to discuss the positive top line results from the ADVANCE study evaluating pimavanserin as a treatment for the negative symptoms of schizophrenia.
On today's call, Steve Davis, our Chief Executive Officer, will provide opening remarks. Following Steve, Dr. Serge Stankovic, our President, will discuss the ADVANCE results in greater detail. Following Steve's closing remarks, we will conduct a Q&A session. Michael Yang, our Chief Commercial Officer; and Elena Ridloff, our Chief Financial Officer, will be also available for Q&A.
I would also like to point
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |